View More View Less
  • 1 Országos Onkológiai Intézet, Budapest, Ráth György u. 7–9., 1122
  • 2 Magyar Honvédség Egészségügyi Központ, Budapest
  • 3 Semmelweis Egyetem, Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

A kannabisz a legnépszerűbb lágy drogok közé tartozik, a kávé, a dohány és az alkohol után világszerte a negyedik legtöbbet fogyasztott pszichoaktív szer. A két legismertebb növényi kannabinoid, a szigorúan ellenőrzött pszichotrop delta-9-tetrahidrokannabinol és a pszichoaktív hatással nem rendelkező, 2004 óta Magyarországon is elérhető, csupán bejelentési kötelezettséggel járó, étrend-kiegészítőnek minősülő kannabidiol. Az orvosi célú kannabisz használatával kapcsolatban, főleg onkológiai indikációban, számos tévhit kering. Közleményünkben összefoglaljuk a kannabisz történetét, hatásmechanizmusát, az onkológiai alkalmazásra jelenleg rendelkezésre álló evidenciákat, a jogi szabályozást, és külön felhívjuk a figyelmet a kannabidiol alkalmazásakor felmerülő potenciális veszélyekre. Orv Hetil. 2020; 161(25): 1035–1041.

  • 1

    Braun IM, Wright A, Peteet J, et al. Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: a nationally representative survey study. J Clin Oncol. 2018; 36: 1957–1962.

  • 2

    Abi-Jaoude E, Chen L, Cheung P, et al. Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2017; 29: 391–400.

  • 3

    Thomas RH, Cunningham MO. Cannabis and epilepsy. Pract Neurol. 2018; 18: 465–471.

  • 4

    Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012; 184: 1143–1150.

  • 5

    Pellesi L, Verga MC, De Maria N, et al. Nabilone administration in refractory chronic diarrhea: a case series. BMC Gastroenterol. 2019; 19: 105.

  • 6

    Goyal H, Singla U, Gupta U, et al. Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol. 2017; 29: 135–143.

  • 7

    Wikipedia. Cannabis. [Wikipédia. Kannabisz.] Available from: https://hu.wikipedia.org/wiki/Kannabisz [accessed: January 20, 2020]. [Hungarian]

  • 8

    Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – regulations in Europe and North America. Eur J Intern Med. 2018; 49: 2–6.

  • 9

    Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018; 19: 833.

  • 10

    Pacher P, Bátkai S, Kunos G, et al. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol. 2005; 168: 599–625.

  • 11

    Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005; 5: 400–411.

  • 12

    Bloomfield MA, Ashok AH, Volkow ND, et al. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature 2016; 539: 369–377.

  • 13

    Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment – a systematic review. J Med Toxicol. 2017; 13: 71–87.

  • 14

    Borgelt LM, Franson KL, Nussbaum AM, et al. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33: 195–209.

  • 15

    Gyires K, Fürst Z. Basics of pharmacology. [A farmakológia alapjai.] Medicina Könyvkiadó, Budapest, 2011. [Hungarian]

  • 16

    Opitz BJ, Ostroff ML, Whitman AC. The potential clinical implications and importance of drug interactions between anticancer agents and cannabidiol in patients with cancer. J Pharm Pract. 2019 Feb 18. . Available from: https://doi.org/10.1177/0897190019828920 [accessed: January 20, 2020].

    • Crossref
    • Export Citation
  • 17

    Product Monograph, NMARINOL®. Abbott Laboratories, Limited. Saint-Laurent, Quebec, 2011. Available from: https://pdf.hres.ca/dpd_pm/00013378.PDF [accessed: January 20, 2020.]

  • 18

    Product Monograph, NCESAMET®, Nabilone. Valeant Canada limitée/Limited. Montreal, Quebec, 2009. Available from: https://pdf.hres.ca/dpd_pm/00007760.PDF [accessed: January 20, 2020].

  • 19

    Product Monograph, NSATIVEX®. GW Pharma Ltd., Toronto, 2012. Available from: https://pdf.hres.ca/dpd_pm/00016162.PDF [accessed: 2020 Jan 20].

  • 20

    The Government of Hungary. National regulation and register on activities with drugs and psychotropic agents. [66/2012. (IV. 2.) Korm. rendelet a kábítószerekkel és pszichotróp anyagokkal, valamint az új pszichoaktív anyagokkal végezhető tevékenységekről, valamint ezen anyagok jegyzékre vételéről és jegyzékeinek módosításáról.] Available from: https://net.jogtar.hu/getpdf?docid=a1200066.kor&targetdate=20180101&printTitle=66/h2012.+%28IV.+2.%29+Korm.+rendelet [accessed: January 20, 2020]. [Hungarian]

  • 21

    The National Assembly of Hungary. Act C of 2012 on the Criminal Code. [2012. évi C. törvény a Büntető Törvénykönyvről. (Available from: https://net.jogtar.hu/getpdf?docid=A1200100.TV&targetdate=&printTitle=2012.+%C3%A9vi+C.+t%C3%B6rv%C3%A9ny) [accessed: January 20, 2020]. [Hungarian]

  • 22

    National Institute of Pharmacy and Nutrition, Hungary. Commitment of the National Pharmaceutical and Food Health Institute on activities with cannabidiol (CBD). [Az Országos Gyógyszerészeti és Élelmezés-Egészségügyi Intézet állásfoglalása a cannabidiollal (CBD) való tevékenységre vonatkozóan.] Available from: https://ogyei.gov.hu/dynamic/OGYEI%20allasfoglalas%20a%20cannabidiollal%20kapcsolatban%20_%2020180821.pdf [accessed: January 20, 2020]. [Hungarian]

  • 23

    Smith LA, Azariah F, Lavender VT, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015; 2015: CD009464.

  • 24

    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. NCCN, Plymouth Meeting, PA. Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [accessed: October 2, 2019].

  • 25

    Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.

  • 26

    Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39: 167–179.

  • 27

    Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757–1762.

  • 28

    Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017; 167: 319–331.

  • 29

    Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002; 20: 567–573.

  • 30

    Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J Clin Oncol. 2006; 24: 3394–3400.

  • 31

    National Comprehensive Cancer Network. NCCN guidelines for adult cancer pain. NCCN, Plymouth Meeting, PA. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf [accessed: November 30, 2019].

  • 32

    Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018; 29(Suppl 4): iv166– iv191.

  • 33

    Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer 2018; 118: 1130–1141.

  • 34

    Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer 2015; 136: 894–903.

  • 35

    de Carvalho MF, Dourado MR, Fernandes IB, et al. Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Arch Oral Biol. 2015; 60: 1750–1755.

  • 36

    Gurney J, Shaw C, Stanley J, et al. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 2015; 15: 897.

  • 37

    Huang YH, Zhang ZF, Tashkin DP, et al. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015; 24: 15–31.

  • 38

    Rocha FC, Dos Santos JG Jr, Stefano SC, et al. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol. 2014; 116: 11–24.

  • 39

    U.S. Food & Drug Administration. What you need to know (and what we’re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. FDA, Silver Spring, MD. Available from: https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis [accessed: December 14, 2019].

  • 40

    U.S. Food & Drug Administration. FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns. FDA, Silver Spring, MD. Available from: https://www.fda.gov/news-events/press-announcements/fda-warns-15-companies-illegally-selling-various-products-containing-cannabidiol-agency-details [accessed: December 14, 2019].

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu